Anthem Biosciences Lists at 27% Premium Amid Strong Demand

Anthem Biosciences made a strong stock market debut, listing at a 26.85% premium to its IPO price of ₹570. The ₹3,395-crore IPO was subscribed 64 times. Despite listing slightly below grey market expectations, experts highlight its robust CRDMO platform, high margins, and long-term growth potential in the biotech space.